Femasys insider buys shares and receives warrants
Femasys Inc. executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, acquired equity-linked interests on August 7, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Femasys Inc. executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, acquired equity-linked interests on August 7, 2026. He purchased 3,125 shares of common stock at $3.20 per share for an aggregate $10,000, and received two warrants for 3,125 shares each with a $2.95 exercise price, one immediately exercisable (subject to Nasdaq-related limitations) and one tied to future revenue and stock-price milestones.
Insider Trade Summary
Net Buyer: 3,125 shares
Net Buy
3 txns
Insider
Mifek Jeffrey Gerald
Role
Chief Clinical-Medical Affairs
Bought
3,125 shs ($10K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock Purchase Warrant F2, F4, F3 | 3,125 | -- | -- |
| Grant/Award | Common Stock Purchase Warrant (Milestone) F2, F4, F5, F3 | 3,125 | -- | -- |
| Purchase | Common Stock F1 | 3,125 | $3.20 | $10K |
Holdings After Transaction:
Common Stock Purchase Warrant — 3,125 contracts (Direct);
Common Stock Purchase Warrant (Milestone) — 3,125 contracts (Direct);
Common Stock — 3,125 shares (Direct)
Footnotes (5)
- F1. The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.
- F2. Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.
- F3. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.
- F4. The reported securities were purchased by the reporting person for an aggregate amount of $10,000.
- F5. The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.
Key Figures
Common shares purchased: 3,125 shares
Purchase price per share: $3.20 per share
Aggregate purchase amount: $10,000
+5 more
8 metrics
Common shares purchased
3,125 shares
Common Stock purchased on August 7, 2026
Purchase price per share
$3.20 per share
Price paid for common stock under Securities Purchase Agreement
Aggregate purchase amount
$10,000
Total paid by reporting person for the reported securities
Regular warrant size
3,125 shares
Common Stock Purchase Warrant underlying common shares
Milestone warrant size
3,125 shares
Common Stock Purchase Warrant (Milestone) underlying common shares
Warrant exercise price
$2.95 per share
Exercise price for both reported common stock purchase warrants
Revenue milestone
$1,500,000
U.S. revenue for any fiscal quarter required for Milestone Date
Regular warrant expiration
2029-08-10
Expiration date of the immediately exercisable common warrant
Key Terms
Common Stock Purchase Warrant, Milestone Date, volume-weighted average price, Nasdaq Capital Market, +1 more
5 terms
Common Stock Purchase Warrant financial
"Holder may, at its option, exercise the Common Warrant, subject to the terms"
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
Milestone Date financial
"The Common Warrant (Milestone) is exercisable only from and after the Milestone Date"
volume-weighted average price financial
"the volume-weighted average price of the Common Stock has satisfied certain price conditions"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
Nasdaq Capital Market financial
"subject to certain limitations, in accordance with rules of the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
registration statement regulatory
"three years after the effective date of a registration statement registering the resale"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did FEMY executive Jeffrey Gerald Mifek buy on August 7, 2026?
Jeffrey Gerald Mifek bought 3,125 shares of Femasys common stock at $3.20 per share. According to the disclosure, the shares were purchased for an aggregate $10,000 under a Securities Purchase Agreement dated August 7, 2026.
What warrants did the FEMY executive receive in this Form 4 filing?
Mifek received two Common Stock Purchase Warrants, each for 3,125 shares of Femasys common stock at an exercise price of $2.95 per share. One is a regular warrant and the other is a Milestone warrant with additional performance conditions.
When can the milestone warrant reported for FEMY be exercised?
The Milestone warrant is exercisable only from and after the Milestone Date. That date requires Femasys to report $1,500,000 U.S. revenue for any fiscal quarter and for its stock’s volume-weighted average price to meet specified conditions.
Are there limits on exercising the FEMY common stock warrants?
Yes. The company states the holder’s ability to exercise the warrant for common shares is subject to limitations under Nasdaq Capital Market rules. The exercise price of $2.95 per share is also subject to adjustment for stock splits and similar corporate actions.
What is the aggregate amount paid by the FEMY insider in this transaction?
The insider paid an aggregate of $10,000 for the securities. This total covers the purchase of 3,125 common shares at $3.20 per share pursuant to a Securities Purchase Agreement dated August 7, 2026.
Is the FEMY Form 4 transaction under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and no footnote describes a trading plan. The transactions are therefore reported without being identified as made under a pre-arranged 10b5-1 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates